Results 111 to 120 of about 11,480 (212)

Platelet Inhibition in Percutaneous Coronary Interventions [PDF]

, 2018
: Mechanical disruption of atherosclerotic plaques at the time of percutaneous coronary intervention (PCI) is a potent stimulus for arterial thrombosis.
Roffi, Marco, Wyss, Christophe
core  

Randomised comparison of femoral versus radial approach for percutaneous coronary intervention using abciximab in acute myocardial infarction: results of the FARMI Trial [PDF]

, 2007
Camille Brasselet, S Tassan, Pierre Nazeyrollas, M. Hamon, David C. Metz   +4 more
openalex   +1 more source

Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction [PDF]

, 2017
Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs withdrawal is much higher than that of surgical bleeding if they are continued.
Chassot, P.-G, Delabays, A., Spahn, D. R.   +2 more
core  

Antiagregación y anticoagulación en síndromes coronarios agudos: niveles de evidencia [PDF]

, 2007
Management of acute coronary syndromes (ACS) has moved rapidly in parallel with our understanding of the pathophysiological basis of the disease. In the eighties, the demonstration of the pivotal role of coronary thrombosis in the etiology of a ACS led ...
Garcia, R. (R.), Paramo, J.A. (José Antonio), Rodriguez, P. (P.), Ruiz-de-Gaona, E. (Estefanía)   +3 more
core  

Disaggregation of In Vitro Preformed Platelet-Rich Clots by Abciximab Increases Fibrin Exposure and Promotes Fibrinolysis [PDF]

, 2001
J.P. Collet, Gilles Montalescot, Claude Lesty, J. Soria, Z. Mishal, Daniel Thomas, Claudine Soria   +6 more
openalex   +1 more source

Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel or both?

Vascular Health and Risk Management, 2006
Matthew A Silva1, Jennifer L Donovan1,3, Pritesh J Gandhi2, Gregory A Volturo31Massachusetts College of Pharmacy and Health Sciences, Department of Pharmacy Practice, Worcester, MA, USA; 2Alexion Pharmaceuticals, Inc., Cheshire, CT, USA; 3UMass Memorial ...
Matthew A Silva, Jennifer L Donovan, Pritesh J Gandhi, Gregory A Volturo   +3 more
doaj  

Effect of Glycoprotein IIb/IIIa Antagonist Abciximab on Monocyte-Platelet Aggregates and Tissue Factor Expression [PDF]

, 2003
Sabine Steiner, Daniela Seidinger, Kurt Huber, Christoph Kaun, Erich Minar, Christoph Kopp   +5 more
openalex   +1 more source

Advances in emerging therapies 2008 [PDF]

, 2009
Higgins, P., Lees, K.R.
core   +1 more source

Correction: Cost-Effectiveness Analysis of Abciximab: A Canadian Hospital Perspective [PDF]

, 1998

openalex   +1 more source

Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials [PDF]

, 2000
A. Michael Lincoff, LeRoy LeNarz, George J. Despotis, Peter K. Smith, Joan E. Booth, Russell Raymond, Shelly Sapp, Catherine F. Cabot, James E. Tcheng, Robert M. Califf, Mark B. Effron, Eric J. Topol   +11 more
openalex   +1 more source